Show simple item record

dc.contributor.authorRenehan, Andrew G
dc.contributor.authorJones, J
dc.contributor.authorPotten, Christopher S
dc.contributor.authorShalet, Stephen M
dc.contributor.authorO'Dwyer, Sarah T
dc.date.accessioned2009-11-23T11:10:40Z
dc.date.available2009-11-23T11:10:40Z
dc.date.issued2000-11
dc.identifier.citationElevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. 2000, 83 (10):1344-50 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid11044360
dc.identifier.doi10.1054/bjoc.2000.1462
dc.identifier.urihttp://hdl.handle.net/10541/86662
dc.description.abstractThis study explored the relationships of serum insulin-like growth factors, IGF-I and IGF-II, and their binding proteins (IGFBP)-2 and IGFBP-3, with key clinicopathological parameters in 92 patients with colorectal cancer (cases). Comparisons were made with 57 individuals who had a normal colonoscopy (controls). Serial changes were examined in 27 cases. As IGF-related peptides are age- and sex-dependent, absolute concentrations were converted to standard deviation scores (SDS). Mean IGF-II SDS were elevated in Dukes A (n = 12, P< 0.001) and Dukes B (n = 25, P< 0.001) cases compared with controls, but not in advanced disease. Compared with controls, mean IGFBP-2 SDS were significantly elevated in patients with Dukes B (P< 0.001), Dukes C (n = 13, P< 0.001) and advanced disease (n = 42, P< 0.0001), with a significant trend from early to advanced disease (one-way ANOVA, P< 0.001). Furthermore, IGFBP-2 SDS were positively related to tumour size (P = 0.01) and fell significantly in patients following curative resection (P = 0.04), suggesting that circulating levels reflect tumour load. We tested the potential tumour marker characteristics of IGFBP-2 SDS against three endpoints: metastasis alone; local pelvic recurrence alone; and metastasis and recurrence combined. The sensitivities for IGFBP-2 alone (>/= + 2SD) were modest at 55%, 46%, and 52%, but in combination with CEA, increased substantially to 90%, 77% and 86%, respectively. We conclude that the serum IGF-II and IGFBP-2 profiles may provide insights into underlying biological mechanisms, and that serum IGFBP-2 may have an adjunct role in cancer surveillance in patients with colorectal cancer.
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subjectCancer Metastasisen
dc.subjectCancer Stagingen
dc.subjectBiological Tumour Markersen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshColorectal Neoplasms
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInsulin-Like Growth Factor Binding Protein 2
dc.subject.meshInsulin-Like Growth Factor Binding Protein 3
dc.subject.meshInsulin-Like Growth Factor I
dc.subject.meshInsulin-Like Growth Factor II
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeoplasm Staging
dc.subject.meshSensitivity and Specificity
dc.subject.meshTumor Markers, Biological
dc.titleElevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Christie Hospital NHS Trust, Manchester, M20 4BX.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThis study explored the relationships of serum insulin-like growth factors, IGF-I and IGF-II, and their binding proteins (IGFBP)-2 and IGFBP-3, with key clinicopathological parameters in 92 patients with colorectal cancer (cases). Comparisons were made with 57 individuals who had a normal colonoscopy (controls). Serial changes were examined in 27 cases. As IGF-related peptides are age- and sex-dependent, absolute concentrations were converted to standard deviation scores (SDS). Mean IGF-II SDS were elevated in Dukes A (n = 12, P< 0.001) and Dukes B (n = 25, P< 0.001) cases compared with controls, but not in advanced disease. Compared with controls, mean IGFBP-2 SDS were significantly elevated in patients with Dukes B (P< 0.001), Dukes C (n = 13, P< 0.001) and advanced disease (n = 42, P< 0.0001), with a significant trend from early to advanced disease (one-way ANOVA, P< 0.001). Furthermore, IGFBP-2 SDS were positively related to tumour size (P = 0.01) and fell significantly in patients following curative resection (P = 0.04), suggesting that circulating levels reflect tumour load. We tested the potential tumour marker characteristics of IGFBP-2 SDS against three endpoints: metastasis alone; local pelvic recurrence alone; and metastasis and recurrence combined. The sensitivities for IGFBP-2 alone (>/= + 2SD) were modest at 55%, 46%, and 52%, but in combination with CEA, increased substantially to 90%, 77% and 86%, respectively. We conclude that the serum IGF-II and IGFBP-2 profiles may provide insights into underlying biological mechanisms, and that serum IGFBP-2 may have an adjunct role in cancer surveillance in patients with colorectal cancer.


This item appears in the following Collection(s)

Show simple item record